Noggin 蛋白, Human (HEK293)

Noggin Protein is a glycosylated cysteine knot chemokine protein. Noggin is a potent bone morphogenetic protein (BMP) antagonist. Noggin Protein antagonizes BMP4-induced hypertension, inhibits angiogenesis, regulates mesenchymal stem cell differentiation, and maintains embryonic stem cell pluripotency. Noggin Protein, Human (HEK293) is a recombinant Noggin protein produced by HEK293 cells.

Noggin Protein 属于 TGF-β 超家族的骨形态发生蛋白 (BMP) 拮抗剂家族。Noggin Protein 是一种糖基化的半胱氨酸结趋化因子蛋白。Noggin Protein 通过与 BMP 结合形成中和复合物，阻止 BMP 与受体结合，从而抑制 BMP 信号传导，影响细胞存活、增殖和分化^[1]。Noggin Protein 可在人动脉内皮细胞、骨髓间充质干细胞中表达^[1]。Noggin Protein 拮抗 BMP4 诱发的高血压、抑制血管生成、调节间充质干细胞分化、维持胚胎干细胞多能性^{[1][2][3][4][5]}。Noggin Protein, Human 由 232 个氨基酸组成，形成共价连接的同型二聚体，具有高亲和力结合 BMP4 的能力。

Noggin Protein, Human (200 ng/mL；3-21 天) 可单独或与炎性细胞因子/Dexamethasone (HY-14648) 协同诱导人间充质干细胞 (HMSC) 中的碱性磷酸酶活性和矿化，上调 BMP-2 和 ActRII 基因表达^[2]。

Noggin Protein, Human (0.45-0.9 mg/kg；皮下渗透泵植入；4 周) 在 C57BL/6 和 apoE^-/- 小鼠中可拮抗 BMP4 诱发的高血压、血管 NADPH 氧化酶活化以及内皮功能障碍^[5]。

1.Measured by its ability to inhibit BMP-2-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells The ED₅₀ for this effect is <2 μg/mL in the presence of 2000 ng/mL of Recombinant Human BMP-2.
2.Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED₅₀ for this effect is <10 ng/mL in the presence of 50 ng/mL of Recombinant Human BMP-4.
3.Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED₅₀ for this effect is <3 ng/mL in the presence of 30 ng/mL of Recombinant Human BMP-4.
4.Measured by its ability to inhibit BMP-4 induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED₅₀ for this effect is 10-100ng/mL in the presence of 200 ng/mL of Recombinant Human BMP 4.

• 
  Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The IC₅₀ is 1.523 ng/mL, corresponding to a specific activity of 6.6×10⁵ units/ mg.

Human

HEK293

Tag Free

Q13253 (Q28-C232)

9241  [NCBI]

Full Length of Mature Protein

QHYLHIRPAPSDNLPLVDLIEHPDPIFDPKEKDLNETLLRSLLGGHYDPGFMATSPPEDRPGGGGGAAGGAEDLAELDQLLRQRPSGAMPSEIKGLEFSEGLAQGKKQRLSKKLRRKLQMWLWSQTFCPVLYAWNDLGSRFWPRYVKVGSCFSKRSCSVPEGMVCKPSKSVHLTVLRWRCQRRGGQRCGWIPIQYPIISECKCSC

Approximately 28-32 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 500 mM NaCl, 2 mM EDTA, pH 7.4 or PBS, pH 7.4 or PBS, pH 7.4, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Kang HW, et al. In vitro and In vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells. FASEB J. 2009;23(12):4126-4134.  [Content Brief]

  [2]. Rifas L. The role of noggin in human mesenchymal stem cell differentiation. J Cell Biochem. 2007 Mar 1;100(4):824-34.  [Content Brief]

  [3]. Chaturvedi G, et al. Noggin maintains pluripotency of human embryonic stem cells grown on Matrigel. Cell Prolif. 2009 Aug;42(4):425-33.  [Content Brief]

  [4]. Chen C, et al. Noggin suppression decreases BMP-2-induced osteogenesis of human bone marrow-derived mesenchymal stem cells in vitro. J Cell Biochem. 2012 Dec;113(12):3672-80.  [Content Brief]

  [5]. Miriyala S, et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation. 2006 Jun 20;113(24):2818-25.Miriyala S, et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation. 2006 Jun 20;113(24):2818-25.  [Content Brief]